SARS-CoV-2 and the COVID-19 disease: a mini review on diagnostic methods

ABSTRACT Coronavirus disease 2019 (COVID-19) is an infectious disease initially reported in China and currently worldwide dispersed caused by a new coronavirus (SARS-CoV-2 or 2019-nCoV) affecting more than seven million people around the world causing more than 400 thousand deaths (on June 8th, 2020). The diagnosis of COVID-19 is based on the clinical and epidemiological history of the patient. However, the gold standard for COVID-19 diagnosis is the viral detection through the amplification of nucleic acids. Although the quantitative Reverse-Transcription Polymerase Chain Reaction (RT-PCR) has been described as the gold standard for diagnosing COVID-19, there are several difficulties involving its use. Here we comment on RT-PCR and describe alternative tests developed for the diagnosis of COVID-19.

[1]  N. Tanner,et al.  Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP , 2020, medRxiv.

[2]  P. Grant,et al.  Extraction-free COVID-19 (SARS-CoV-2) diagnosis by RT-PCR to increase capacity for national testing programmes during a pandemic , 2020, bioRxiv.

[3]  LAMP-Seq: Population-Scale COVID-19 Diagnostics Using a Compressed Barcode Space , 2020 .

[4]  J. Y. Kim Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR , 2020, Journal of Korean medical science.

[5]  R. Lu,et al.  Three Novel Real-Time RT-PCR Assays for Detection of COVID-19 Virus , 2020, China CDC weekly.

[6]  F. Grosveld,et al.  Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[7]  Tiangang Liu,et al.  Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan , 2020, medRxiv.

[8]  D. Wang,et al.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.

[9]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[10]  Daniel C. Baumgart,et al.  Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management , 2020, Clinical Gastroenterology and Hepatology.

[11]  Moon-Woo Seong,et al.  Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea. , 2020, Annals of laboratory medicine.

[12]  J. Rocklöv,et al.  COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures , 2020, Journal of travel medicine.

[13]  Xiaobo Yu,et al.  SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution , 2020, bioRxiv.

[14]  Ian Goodfellow,et al.  A blueprint for the implementation of a validated approach for the detection of SARS-Cov2 in clinical samples in academic facilities , 2020, bioRxiv.

[15]  L. Lopalco,et al.  Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art , 2020, Frontiers in Immunology.

[16]  R. Soto-Rifo,et al.  SARS-CoV-2 detection from nasopharyngeal swab samples without RNA extraction , 2020, bioRxiv.

[17]  Scott Tighe,et al.  Direct RT-qPCR detection of SARS-CoV-2 RNA from patient nasopharyngeal swabs without an RNA extraction step , 2020, PLoS biology.

[18]  Jaber Aslanzadeh,et al.  Preventing PCR amplification carryover contamination in a clinical laboratory. , 2004, Annals of clinical and laboratory science.

[19]  D. Cummings,et al.  A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease , 2020, medRxiv.

[20]  Y. Teo,et al.  Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review , 2020, Journal of clinical medicine.

[21]  Zhenhua Chen,et al.  Rapid and Sensitive Detection of anti-SARS-CoV-2 IgG, Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay , 2020, Analytical chemistry.

[22]  Carol H. Yan,et al.  Association of chemosensory dysfunction and COVID‐19 in patients presenting with influenza‐like symptoms , 2020, International forum of allergy & rhinology.

[23]  J. Xiang,et al.  Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold- Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19) , 2020, medRxiv.

[24]  Yunbao Pan,et al.  Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients , 2020, Journal of Infection.

[25]  SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution , 2020, ACS central science.

[26]  Lei Liu,et al.  Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections , 2020, medRxiv.

[27]  The clinical data from 19 critically ill patients with coronavirus disease 2019: a single-centered, retrospective, observational study , 2020, Journal of Public Health.

[28]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[29]  K. Krogfelt,et al.  Evaluation of nine commercial SARS-CoV-2 immunoassays , 2020, medRxiv.

[30]  Y. Yazdanpanah,et al.  Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients , 2020, Emerging infectious diseases.

[31]  Geneviève Pépin,et al.  Optimization of SARS-CoV-2 detection by RT-QPCR without RNA extraction , 2020, bioRxiv.

[32]  Dae-Gyun Ahn,et al.  Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19) , 2020, Journal of microbiology and biotechnology.

[33]  Shaoqiang Li,et al.  Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis , 2020, Journal of medical virology.

[34]  Eriko,et al.  Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR assays , 2020 .

[35]  Richard L. Doty,et al.  Smell dysfunction: a biomarker for COVID‐19 , 2020, International forum of allergy & rhinology.

[36]  A. Tahamtan,et al.  Real-time RT-PCR in COVID-19 detection: issues affecting the results , 2020, Expert review of molecular diagnostics.

[37]  Heng Zhu,et al.  Overview of Protein Microarrays , 2013, Current protocols in protein science.

[38]  A. Singh,et al.  COVID-19: From bench to bed side , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[39]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[40]  P. Horby,et al.  A novel coronavirus outbreak of global health concern , 2020, The Lancet.

[41]  H. Rothan,et al.  The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.

[42]  Z. Tong,et al.  Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020 , 2020, Emerging infectious diseases.

[43]  Jianfeng Zhang,et al.  CT imaging features of 4121 patients with COVID‐19: A meta‐analysis , 2020, Journal of medical virology.

[44]  Yuyi Wang,et al.  Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures , 2020, Journal of medical virology.

[45]  T. Qin,et al.  Epidemiological and Clinical Characteristics of 26 Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Carriers , 2020, The Journal of Infectious Diseases.

[46]  Daeui Park,et al.  Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2 , 2020, bioRxiv.

[47]  A. Ługowska,et al.  Laboratory diagnosis of the Niemann-Pick type C disease: an inherited neurodegenerative disorder of cholesterol metabolism , 2019, Metabolic Brain Disease.

[48]  Xiaowei Li,et al.  Molecular immune pathogenesis and diagnosis of COVID-19 , 2020, Journal of Pharmaceutical Analysis.

[49]  Jochen M. Schwenk,et al.  Current applications of antibody microarrays , 2018, Clinical Proteomics.

[50]  Chaochao Tan,et al.  C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early , 2020, Journal of medical virology.

[51]  Guillaume Carissimo,et al.  Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein , 2020, bioRxiv.

[52]  Russell B. Fletcher,et al.  Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia , 2020, Science Advances.

[53]  Season Wong,et al.  The Potential Use of Unprocessed Sample for RT-qPCR Detection of COVID-19 without an RNA Extraction Step , 2020, bioRxiv.

[54]  L. Vaira,et al.  Anosmia and Ageusia: Common Findings in COVID‐19 Patients , 2020, The Laryngoscope.

[55]  Yunbao Pan,et al.  Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients , 2020, Journal of Infection.

[56]  Jaegyun Lim,et al.  Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR , 2020, Journal of Korean medical science.

[57]  Qi Jin,et al.  Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.